Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/29/2005US20050215641 Compositions comprising reverse isomers of conjugated linoleic acid
09/29/2005US20050215640 HMB compositions and uses thereof
09/29/2005US20050215639 Disinfectant with activity against hepatitis b virus
09/29/2005US20050215637 Tuberculosis treatment
09/29/2005US20050215636 Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
09/29/2005US20050215635 Diarylheptanoid compounds and uses thereof
09/29/2005US20050215634 Regulation of cell membrane-mediated effects
09/29/2005US20050215633 Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means
09/29/2005US20050215632 Preventive or remedy for hypertension
09/29/2005US20050215631 such as N-[2-hydroxy-3-(4-trifluoromethylphenoxy)propyl]-N'-2 phenethyl-urea; appetite suppressants for treatment of obesity
09/29/2005US20050215630 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
09/29/2005US20050215629 PTPase inhibitors and methods of using the same
09/29/2005US20050215628 Andrographolide and analogues as inhibitors of TNFalpha and IL-1beta expression
09/29/2005US20050215627 Application of substances acting as cascade inhibitors of the Raf/MEK/ERK signaling cascade for the production of a drug against DNA and RNA viruses
09/29/2005US20050215625 Combination therapy for anticoagulation
09/29/2005US20050215624 Regulation of nad(p)h oxidase growth and transcription in melanoma cells
09/29/2005US20050215623 Use of a thio-functional acid such as 2-hydroxy-4-(methylthio)butanoic acid; fish food
09/29/2005US20050215622 Salts of the dimethylaminoethylamine amide of lipoic acid and their preparation from lipoic acid, carbonyldiimidazole, dimethylaminoethylamine, and an acid, especially maleic or fumaric acid; collagenase, elastase and tyrosinase inhibitors; antioxidants; cosmetics for treating skin disorders
09/29/2005US20050215621 Method of treating amyloid beta precursor disorders
09/29/2005US20050215620 Method of treating amyloid beta precursor disorders
09/29/2005US20050215618 Treating vascular events with statins by inhibiting PAR-1 and PAR-4
09/29/2005US20050215617 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
09/29/2005US20050215616 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol; treating vaginal and skin atrophy
09/29/2005US20050215615 Medical compositions for intravesical treatment of bladder cancer
09/29/2005US20050215613 with indazole or thienopyrazole compounds such as 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole
09/29/2005US20050215612 Anticancer agents; such as succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester, sodium salt; inhibit cancer cell growth
09/29/2005US20050215611 Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
09/29/2005US20050215610 Such as 3-(4-(2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoylamino)-imidazol-1-yl)-butyric acid methyl ester; secretase, A beta -peptide inhibitor; neurogenerative and neurological diseases: Alzheimer's disease; Notch signaling pathway inhibitor; antiinflammatory agent, asthma, autoimmune diseases
09/29/2005US20050215609 Novel uses of prostaglandin d2, prostaglandin d2 agonist and prostaglandin d2 antagonist
09/29/2005US20050215608 2-(pyrazol-1-yl)thiazole compounds; obesity and type II diabetes; modulators of the mitochondrial protein uncoupling protein 3 (UCP3); treating retinoid X receptor (RXR) modulated conditions; e.g. 2-(4-carboxy-5-methylpyrazol-1-yl)-4-(p-trifluoromethylphenyl)thiazole
09/29/2005US20050215607 Drug composition for prevention or inhibition of advance of diabetic complication
09/29/2005US20050215606 Use of parathyroid hormone-related protein(pthrp) in the diagnosis and treatment of chronic lung disease and other pathologies
09/29/2005US20050215605 Preterm labor, premature birth, dysmenorrhea; inhibitors of the prostaglandin F2 alpha receptor; e.g. 3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide
09/29/2005US20050215604 Combination therapies with epothilones and carboplatin
09/29/2005US20050215603 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
09/29/2005US20050215601 Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
09/29/2005US20050215600 Polymorphs of torsemide hydrochloride and process for production thereof
09/29/2005US20050215598 Phenylalanine derivatives
09/29/2005US20050215596 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
09/29/2005US20050215594 Diabetes, obesity, urogenital disorders, cardiovascular disorders, atherosclerosis; 4-[(2R)-2-(([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid for example
09/29/2005US20050215593 Kaposi's sarcoma; Crohn's disease
09/29/2005US20050215592 Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman
09/29/2005US20050215590 Formamide derivatives for the treatment of diseases
09/29/2005US20050215589 Inhibitors of 5-HT2A receptor
09/29/2005US20050215588 Pyridyl cyanoguanidine compounds, e.g., 1-[2-(4-Piperidyl)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chloro-phenoxy)-1-hexyl)-N-guanidino]-pyridinium chloride, hydrochloride; human and veterinary therapy of proliferative diseases such as cancers
09/29/2005US20050215585 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
09/29/2005US20050215584 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
09/29/2005US20050215583 SNS-595 and methods of using the same
09/29/2005US20050215582 Substituted pyrrolopyridines
09/29/2005US20050215581 Administering the compound N-{2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl}morpholine-4-carboxamide inducing cytokine biosynthesis; Viricides; anticancer agents; immunology moderators
09/29/2005US20050215580 Tetrahydrocarboline compounds as anticancer agents
09/29/2005US20050215579 consisting of lung, renal, prostate, uterine, melanoma and breast tumors; cyclodextrin inclusion compounds aid solubility
09/29/2005US20050215577 Tetrahydrocarbazoles and derivatives
09/29/2005US20050215576 antagonists of calcitonin gene-related peptide receptors (CGRP-receptor); 3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl 4-(1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate for example
09/29/2005US20050215575 Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
09/29/2005US20050215574 4-anilino quinazoline derivatives as antiproliferative agents
09/29/2005US20050215573 Novel inhibitors of glutaminyl cyclase
09/29/2005US20050215572 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
09/29/2005US20050215571 Therapeutic combination for cognititon enhancement and psychotic disorders
09/29/2005US20050215570 Process for the preparation of N-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
09/29/2005US20050215569 Inhibiting sodium ion flux through voltage dependent sodium channelswith pyrazopyrimidines for treatment of nervous system disorders, and for treatment of pain or inflammation
09/29/2005US20050215568 Substituted oxetanes, method of making, and method of use thereof
09/29/2005US20050215567 1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
09/29/2005US20050215565 Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents
09/29/2005US20050215564 Methods and compositions for treating hyperproliferative conditions
09/29/2005US20050215562 Methods for treating protein aggregation disorders
09/29/2005US20050215561 Pharmaceutical dosage forms and compositions
09/29/2005US20050215560 5-{2-[4-[1-(4-fluoro-2-hydroxy-phenyl)-methanoyl]-piperidine-1-yl]-(ethyl or propyl)amino}-(optional 2-alkyl)-2H-pyridazine-3-one; hydrogenation of the isoxazolyl-alkylamino-pyridazinone; anxiolytic agents
09/29/2005US20050215559 2-substituted, especially 2-amino-substituted, e.g., [N-(1-ethyl)propyl]-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine; bind with high affinity and high selectivity to CRF1 receptors and are used to treat central nervous system disorders
09/29/2005US20050215558 Methods of identifying responders to dopamine agonist therapy
09/29/2005US20050215557 For therapy and prophylaxis of inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis or rheumatoid arthritis etc
09/29/2005US20050215556 Macrocyclic kinase inhibitors
09/29/2005US20050215554 viricides; therapy for genetic engineered virus; polymerase inhibitor
09/29/2005US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers
09/29/2005US20050215552 synergistic admnistration of a weight-loss promoting benz(is)oxazole anticonvulsant and a bupropion metabolite; hypotensive, antidiabetic, anticholesterol agents; norepinephrine or dopamine agonists
09/29/2005US20050215551 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders
09/29/2005US20050215550 Pyrazole-derived kinase inhibitors and uses thereof
09/29/2005US20050215549 TACE inhibitors
09/29/2005US20050215548 Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide
09/29/2005US20050215547 Optically active pyridine derivative and a medicament containing the same
09/29/2005US20050215545 Methods of treating HIV infection
09/29/2005US20050215544 Methods of treating HIV infection
09/29/2005US20050215543 Methods of treating HIV infection
09/29/2005US20050215542 Compounds for the treatment of diseases
09/29/2005US20050215541 Alzheimer's disease; benzodiazapines
09/29/2005US20050215540 Administering 4-substituted-6 or 7or 8 or 9-alkoxy-2,3,4,5-tetrahydro-1,4-benzothiazepines in which the 4-substitution is a carbonyl group such as oxaloyl and the ring sulfur may be oxidized; for increasing binding of FKBP12.6 to RyR2 or limiting a decrease in the level of RyR2-bound FKBP12.6
09/29/2005US20050215538 Method of treating human skin and a skin care composition for use in such a method
09/29/2005US20050215537 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
09/29/2005US20050215536 Sequential SPRM/ progestin treatment
09/29/2005US20050215535 Sequential SPRM/progestin treatment
09/29/2005US20050215534 Antiinflammatory agents; asthma; chronic obstructive pulmonary disease; dermatitis; antiallergens; antitumor agents; Aida; antiischemic agents; arrhythmia
09/29/2005US20050215533 Administering to mammal an effective amount of sulfaphenazole wherein the administered sulfaphenazole substantially reduces the amount of infracted tissue
09/29/2005US20050215532 Tetracycline compounds for treatment of cryptosporidium parvum related disorders
09/29/2005US20050215531 Use of edg receptor binding agents in cancer
09/29/2005US20050215530 Combination therapy for the treatment of cancer
09/29/2005US20050215529 Method of treating oxidative stress-associated conditions with isopentenyl diphosphate
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215526 Melanin concentrating hormone receptor antagonist
09/29/2005US20050215525 Anti-infective phosphonate analogs
09/29/2005US20050215524 Methods and compositions for improving photodynamic therapy through administration of lipids
1 ... 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 ... 7860